Across TCGA pan-cancer cohorts, UNK Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated UNK data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher UNK Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UNK expression acts as an unfavorable survival marker.
STAD, PRAD, and CESC are the cancer types where UNK Mutation most reproducibly stratifies survival.